表紙
市場調查報告書

ESMO會議報告 (2019年)

2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

出版商 Datamonitor Healthcare 商品編碼 914886
出版日期 內容資訊 英文 117 Pages
商品交期: 最快1-2個工作天內
價格
ESMO會議報告 (2019年) 2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report
出版日期: 2019年10月18日內容資訊: 英文 117 Pages
簡介

歐洲臨床腫瘤學會 (ESMO)的年度會議,2019年9月27日∼10月1日,在巴塞隆納 (西班牙) 召開。

本報告提供含卵巢癌症的PARP抑制劑的新資料,ESMO會議的重要專題的摘要,加上相關的資料相關的系統性資訊。

摘要

關於作者

免責聲明

藥物的摘要

  • 膽道癌症
  • 膀胱癌
  • 乳癌
  • 大腸癌症
  • 食道癌症
  • 胃癌
  • 頭頸椎癌症
  • 卵巢癌症
  • 前列腺癌症
  • 固態腫瘤
  • 甲狀腺癌症

ESMO活動的清單

目錄
Product Code: #BMT

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for non-small lung cancer and Kisqali for breast cancer.

This post-meeting report features summaries of a few key topics along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.

Table of Contents

Summary

About the Author

Disclaimer

Drug Abstracts

Biliary Tract Cancer

  • Pemigatinib for Biliary Tract Cancer (INCY, Phase III)
  • Tibsovo for Biliary Tract Cancer (AGIO, Phase III)

Bladder Cancer

  • Enfortumab Vedotin for Bladder Cancer (Astellas, BLA)
  • Sacituzumab Govitecan for Bladder Cancer (IMMU, Phase II)
  • Tecentriq for Bladder Cancer (RHHBY, Approved)

Breast Cancer

  • G1T48 for Breast Cancer (G1 Therapeutics, Phase I)
  • Keytruda for Breast Cancer (MRK, Phase III)
  • Keytruda for Breast Cancer (MRK, Phase III)
  • Kisquali for Breast Cancer (NVS, Approved)
  • Trilaciclib for Breast Cancer (G1 Therapeutics, Phase II)
  • Verzenio for Breast Cancer (LLY, Approved)

Colorectal Cancer

  • AMG 510 for Colorectal Cancer (CRC) (AMGN, Phase I)
  • Braftovi for Colorectal Cancer (CRC) (PFE, Phase III)
  • Tucatinib for Colorectal Cancer (CRC) (PFE, Phase III)

Esophageal Cancer

  • Opdivo for Esophageal Cancer (BMY, Phase III)

Gastric Cancer

  • Margetuximab for Gastric Cancer (MGNX, Phase II)

Head and Neck Cancer

  • Debio 1143 for Head and Neck Cancer (Debiopharm, Phase II)
  • Monalizumab for Head and Neck Cancer (AZN, Phase II)
  • Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)
  • Opdivo for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (BMY, Approved)
  • Tecentriq for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (RHHBY, Phase III)
  • Non-Small Cell Lung Cancer (NSCLC)
  • AMG 510 for Non-Small Cell Lung Cancer (NSCLC) (AMGN, Phase I)
  • Opdivo for Non-Small Cell Lung Cancer (NSCLC) (BMY, Approved)
  • Tagrisso for Non-Small Cell Lung Cancer (NSCLC) (AZN, Approved)
  • Tecentriq for Non-Small Cell Lung Cancer (NSCLC) (RHHBY, Approved)

Ovarian Cancer

  • AVB-500 for Ovarian Cancer (ARAV, Phase II)
  • Lynparza for Ovarian Cancer (AZN, Approved)
  • M6620 for Ovarian Cancer (MKGAY, Phase II)
  • Mirvetuximab Soravtansine for Ovarian Cancer (IMGN, Phase III)
  • Veliparib for Ovarian Cancer (ABBV, Phase III)
  • Zejula for Ovarian Cancer (GSK, Approved)

Prostate Cancer

  • Erleada for Prostate Cancer (JNJ, Approved)
  • Lynparza for Prostate Cancer (AZN, Phase III)
  • Rubraca for Prostate Cancer (CLVS, Phase III)
  • SM-88 for Prostate Cancer (TYME, Phase II)
  • Zejula for Prostate Cancer (GSK, Phase III)
  • Renal Cell Cancer (RCC)
  • Mavorixafor for Renal Cell Cancer (RCC) (XFOR, Phase II)
  • MK-6482 for Renal Cell Cancer (RCC) (MRK, Phase II)
  • Tivopath (Oncology) for Renal Cell Cancer (RCC) (AVEO, Phase III)

Solid Tumors

  • ALRN-6924 for Solid Tumors (ALRN, Phase II)

Thyroid Cancer

  • Selpercatinib for Thyroid Cancer (LLY, Phase II)

List of Biomedtracker ESMO Events